Nicotine Effects on Endophenotypes of Schizophrenia

NCT ID: NCT01315002

Last Updated: 2015-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 121 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-07-31
• Study Completion Date: 2012-03-31

Brief Summary

The purpose of this study is to test the effects of nicotine on cognition with the following schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Schizophrenia patients, unaffected first-degree relatives of schizophrenia patients and healthy controls receive transdermal nicotine in a double-blind, placebo-controlled, crossover study.

Detailed Description

Convergent findings suggest that an altered neuronal nicotinic acetylcholine receptor system may contribute to the pathophysiology of schizophrenia. Nicotine consumption through cigarette smoking might represent a form of self-medication in schizophrenia as nicotine reduces cognitive and physiological deficits in schizophrenia. The present study aims to investigate how nicotine affects attentional and executive schizophrenia endophenotypes and how genetic polymorphisms relating to the cholinergic system might play a role in inter-individual differences in the magnitude of nicotine effects.

Schizophrenia patients, first-degree relatives of schizophrenia patients as well as healthy controls will receive transdermal nicotine in a double-blind, placebo-controlled, crossover study and will be assessed with prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Subjects will be overnight-abstinent smokers and non-smokers. However, the investigators will particularly test non-smokers in order to eliminate confounding effects of nicotine withdrawal and reinstatement.

Main hypotheses:

• Schizophrenia patients will perform worse than matched controls in all cognitive tests (validating our endophenotypes).
• Nicotine administration will enhance cognitive performance in overnight-abstinent smokers.
• Improvement of cognitive performance in smokers with schizophrenia will be stronger than in control smokers.
• Improvement of cognitive performance in smoking first-degree relatives of schizophrenia patients will be stronger than in control smokers.
• Nicotine administration will affect cognitive functioning in non-smoking subjects.
• Nicotine administration will improve cognitive functioning in non-smoking schizophrenia patients.
• The effects of nicotine in non-smoking subjects are stronger in those subjects who are cognitively more impaired (i.e. performing below the median of the respective group).

The present research contributes to the issue whether nicotinic cholinergic receptor agonists may have therapeutic value in the treatment of cognition in schizophrenia.

Conditions

Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Nicotine Patch

Transdermal nicotine patch

Group Type: ACTIVE_COMPARATOR

Transdermal nicotine patch

Intervention Type: DRUG

7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)

Placebo patch

Placebo patch

Group Type: PLACEBO_COMPARATOR

Placebo patch

Intervention Type: DRUG

Placebo patch

Interventions

Transdermal nicotine patch

7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)

Intervention Type: DRUG

Placebo patch

Placebo patch

Intervention Type: DRUG

Other Intervention Names

NiQuitin Clear, GlaxoSmithKline Germany; band-aid by Fink and Walter GmbH, Germany

Eligibility Criteria

Inclusion Criteria

Patients:

• Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) diagnosis of schizophrenia
• age 18-55 years old
• able to provide informed consent
• treated with antipsychotic medications at a stable dose for at least 6 weeks
• normal or corrected to normal vision
• smokers (Fagerström Test for Nicotine Dependence > 4)
• non-smokers (< 100 cigarettes/lifetime, not having smoked in the past year)

Controls:

• age 18-55 years old
• able to provide informed consent
• normal or corrected to normal vision
• smokers (Fagerström Test for Nicotine Dependence > 4)
• non-smokers (< 100 cigarettes/lifetime, not having smoked in the past year)

Unaffected First-Degree Relatives of Schizophrenia Patients:

• having an adult first-degree relative (sibling, parent, child) with a DSM IV diagnosis of schizophrenia

Exclusion Criteria

Patients:

• substance dependence
• clinical instability
• changes in medication in the last 6 weeks
• anticholinergic medication
• untreated hypertension
• cardiovascular disease
• insulin-dependent diabetes mellitus
• phaeochromocytoma
• uncontrolled hyperthyroidism
• renal or hepatic impairment
• central nervous system disease
• pulmonary disease
• generalised dermatological disorders (neurodermatitis, psoriasis, chronic dermatitis, urticaria, etc.)
• gastric or intestinal ulcer
• hypersensitivity to nicotine
• allergy to patches
• women: pregnancy, lactation

Controls:

• substance dependence
• having a first-, second-, or third-degree relative with a psychotic disorder
• DSM IV Axis I disorder
• anticholinergic medication
• untreated hypertension
• cardiovascular disease
• insulin-dependent diabetes mellitus
• phaeochromocytoma
• uncontrolled hyperthyroidism
• renal or hepatic impairment
• central nervous system disease
• pulmonary disease
• generalised dermatological disorders (neurodermatitis, psoriasis, chronic dermatitis, urticaria, etc.)
• gastric or intestinal ulcer
• hypersensitivity to nicotine
• allergy to patches
• women: pregnancy, lactation

Unaffected First-Degree Relatives of Schizophrenia Patients:

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

German Research Foundation

OTHER

Sponsor Role: collaborator

University Hospital, Bonn

OTHER

Sponsor Role: lead

Responsible Party

Nadine Petrovsky

PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael Wagner, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bonn

Wolfgang Maier, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bonn

Other Identifiers

2008-001362-90

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NICSZ001

Identifier Type: -

Identifier Source: org_study_id